CE Disclosures and Faculty Information

• TARGET AUDIENCE
  
  This activity is intended for medical, surgical and radiation oncologists, thoracic surgeons and other allied professionals involved in the treatment of non-small cell lung cancer (NSCLC).
  
  OVERVIEW OF ACTIVITY
  
  Representing one of the most dynamic areas of medical oncology today, NSCLC has witnessed the recent emergence of numerous data sets affecting current treatment decision-making for patients diagnosed with this lethal disease. Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making management decisions in the face of this rapidly evolving clinical environment. But despite the existence of these tools, many areas of controversy persist within academic and community settings. These video proceedings from an interactive Grand Rounds activity combine the perspectives of 7 lung cancer investigators on a number of controversial issues in the diagnosis and treatment of NSCLC with a review of emerging research information in this area to assist medical oncologists and other allied cancer professionals with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Counsel patients with localized NSCLC about the risk-adjusted, long-term clinical effects of adjuvant chemotherapy.
  • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
  • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of maintenance biologic therapy and/or chemotherapy.
  • Recognize the effects of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR tyrosine kinase inhibitors, monoclonal antibodies and other emerging molecular-targeted agents.
  • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.
  • Employ case-based learning to refine or validate your existing NSCLC treatment algorithms.

  ACCREDITATION STATEMENT
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  This CME activity consists of a video component. The participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Chandra P Belani, MD
  Miriam Beckner Distinguished Professor of Medicine
  Penn State College of Medicine
  Deputy Director, Penn State Hershey Cancer Institute
  Hershey, Pennsylvania
  
  Advisory Committee: Genentech BioOncology, Lilly USA LLC, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC.
  
  Edward S Kim, MD
  Chair, Department of Solid Tumor Oncology and Investigational Therapeutics
  Donald S Kim Distinguished Chair for Cancer Research
  Levine Cancer Institute
  Carolinas Healthcare System
  Charlotte, North Carolina
  
  Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Oncology; Paid Research: Genentech BioOncology, Lilly USA LLC.
  
  Corey J Langer, MD
  Director of Thoracic Oncology, Abramson Cancer Center
  Professor of Medicine, University of Pennsylvania
  Vice Chair, Radiation Therapy Oncology Group
  Philadelphia, Pennsylvania
  
  Advisory Committee and Consulting Agreements: Allos Therapeutics, ARIAD Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, OSI Oncology, Pfizer Inc; Data and Safety Monitoring Committee: Amgen Inc.
  
  Alan B Sandler, MD
  Professor of Medicine
  Division Chief, Hematology and Medical Oncology
  DeArmond Chair for Clinical Cancer Research
  Co-Director, Clinical Management Research
  Associate Director for Clinical Research
  Knight Cancer Institute
  Oregon Health and Science University
  Portland, Oregon
  
  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Consulting Agreements: Allos Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.
  
  Lecia V Sequist, MD, MPH
  Assistant Professor of Medicine
  Harvard Medical School
  Center for Thoracic Cancers
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee: Daiichi Sankyo Inc, GlaxoSmithKline; Paid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Merrimack Pharmaceuticals, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi.
  
  Mark A Socinski, MD
  Professor of Medicine and Thoracic Surgery
  Director, Lung Cancer Section
  Division of Hematology/Oncology
  Co-Director, UPMC Lung Cancer Center of Excellence
  Co-Director, Lung and Thoracic Malignancies Program
  University of Pittsburgh, UPMC Cancer Pavilion
  Pittsburgh, Pennsylvania
  
  Paid Research: Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.
  
  Heather Wakelee, MD
  Assistant Professor of Medicine
  Division of Oncology
  Stanford University School of Medicine
  Stanford Cancer Institute
  Stanford, California
  
  Paid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, Genentech BioOncology and Lilly USA LLC.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: July 2012
  Expiration date: July 2013